Share price: 160.00p

AGM Statement

9th May 2017

Cello Group plc (AIM:CLL), the pharmaceutical and consumer strategic marketing group, announces that at the Annual General Meeting today, Chairman Allan Rich will say:

“The Group has had a good start to the year and the outlook at this relatively early stage is pleasing.

Cello Health has made a strong start to the year, particularly in the crucial US market. The overall income pipeline is good. Defined Health, which joined the Group in early February, has performed very well in its first couple of months and has a strong outlook. Following the recent fundraise, the Group is making encouraging progress in pursuit of its acquisition led strategy for growth, to complement the good rate of organic growth of Cello Health.

Cello Signal has also made a good start to the year and has a solid bookings pipeline. The transition towards web based systems solutions continues to progress rapidly across the business, with a pleasing level of wins so far this year. Overall, due to the timing of some key contracts this year, the business will be somewhat more weighted to the second half. This is not thought likely to affect the overall first half profit delivery for the Group.

Pulsar continues its rapid rate of growth and its entry into the US market this year is proceeding well. The data supply side of the product continues to evolve quickly and positively.

The Group’s balance sheet remains very strong.

The Board is confident of a successful full year for 2017.”




Cello Group plc

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director



Bobbie Hilliam

020 7397 8927


Richard Oldworth

Jamie Hooper

Madeleine Seacombe

020 7466 5000

This information is provided by RNS

The company news service from the London Stock Exchange


Contact Us


Cello Health plc

Queens House

8-9 Queen Street



Registered Office

Queens House

8-9 Queen Street



Company Registered

in England no.05120150